SAGE Therapeutics Inc SAGE released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive disorder (MDD).
The news immediately propelled Sage's stock, rocketing it past previous highs to $169.58. Cowen thinks there’s still upside.
Cowen analyst Ritu Baral maintained an Outperform rating on Sage and raised his price target from $135 to $202.
The treatment demonstrated statistical significance within 12 hours, sustained efficacy for four weeks, and met primary endpoints with “impressive, rapid, durable effectiveness.”
It also showed a positive safety profile with broad tolerance and common adverse effects. Previous concerns about elevated sedation levels were largely mitigated by night-time dosing and an altered capsule formulation.
“With a unique mechanism, superior efficacy, faster onset and good tolerability (as well potential benefits on sleep) compared to SSRIs, '217 can potentially become the first-line treatment for MDD with a potential for premium pricing to even branded SSRIs,” Baral wrote, noting that the program is ready for Phase 3.
Baral expects regulatory approval particularly considering the indication’s fast-track designation and Sage’s plan to pursue breakthrough designation. She anticipates peak MDD sales of $1.5 billion with potential additional sales for Parkinson’s and Essential tremor.
At time of publication, Sage was trading up 76.5 percent at a rate of $162.22.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.